Profiling Serum Oxylipin Metabolites Across Melanoma Subtypes and Immunotherapy Responders
Despite limited variation in serum oxylipin molecular species by subtype and response status, we observed significant differences in prostaglandin J<sub>2</sub>, which could serve as a potential biomarker for immune checkpoint inhibitor therapy response in melanoma.
Authors
- Jaqueline Turner
- Alexander Goodman
- William Allen Robinson (ORCID: https://orcid.org/0000-0003-1875-9691)
- Kasey L. Couts (ORCID: https://orcid.org/0000-0002-2088-2229)
- Richard P. Tobin (ORCID: https://orcid.org/0000-0003-3890-4534)
- Morgan MacBeth (ORCID: https://orcid.org/0000-0003-1299-0999)
- Kylie Michel
Institutions
- Rocky Vista University (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Metabolites
- Published
- 2025-12-23
- DOI
- https://doi.org/10.3390/metabo16010014
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Moore Family Foundation
- Cancer Center, University of Colorado
- University of Colorado School of Medicine, Anschutz Medical Campus